Xenon Pharmaceuticals Inc - XENE Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The EV/EBITDA ratio, accounting for debt and amortization, reflects the dynamics of the potassium channel activator for treating depression and epilepsy, with the current parameter standing at 0.00. Revenue stability is driven by multi-year therapy for patients with neurological pathologies. High physician confidence and the precision of clinical tests confirm the status of Xenon Pharmaceuticals (XENE) as an authoritative developer in neuromedicine.
Financial and market metric breakdowns for Xenon (XENE)
- market price and analyst price targets:
- issuer market value details:
- book value of equity indicators:
- debt and liquidity data:
Debt to Equity Xenon Pharmaceuticals|XENE - Long-Term Liabilities to Equity|Short-Term Debt to Capital Xenon Pharmaceuticals Inc|XENE - Aggregate Debt Obligations|Debts to Book Capitalization Xenon Pharmaceuticals|XENE - Company Long-Term Debts|Company Short-Term Debt Xenon Pharmaceuticals|Quick Liquidity xenon-pharma.com
- business earnings and investment ratios data:
XENE - Net Income|Projected Future Earnings Xenon Pharmaceuticals|XENE - P/E Multiple|Forward P/E Multiple Xenon Pharmaceuticals Inc.|XENE - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Xenon Corp|XENE - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Xenon Pharmaceuticals|XENE - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months xenon-pharma.com|XENE - Net earnings per one share growth for the current year|Earnings growth forecast for next year Xenon Pharmaceuticals
- sales and revenue indicators:
Summary company analysis:Xenon Corp XENE
The fundamental attractiveness of the asset is determined by the ratio of the total enterprise value to its operating profit before depreciation, taxes, and interest. The current EV/EBITDA multiple of Xenon Pharmaceuticals (XENE) reflects the real value of Xenon Pharmaceuticals accounting for debt, which is critical for a biotech company with patent protection and the potential for high margins upon the market entry of epilepsy drugs.
Competitors of Xenon Pharmaceuticals
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation VKTX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Supernus|Company Value to EBITDA catalystpharma.com CPRX|Enterprise Value to EBITDA Ratio DNLI (Denali Therapeutics Inc.)|HRMY - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biohaven Ltd. BHVN|AMLX (Amylyx) - Company Value to Operating Income Before Depreciation Ratio|Trevi Therapeutics Inc - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation PRAX (Praxis Precision Medicines)|AVXL: EV/EBITDA Multiple|CBLL - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization prothena.com|Enterprise Value to EBITDA Ratio Alector (ALEC)|Enterprise Value to EBITDA Ratio ANNX (annexonbio.com)|OMER - Company Value to EBITDA|EV/EBITDA Multiple NGNE (Neurogene Inc)|EV/EBITDA Multiple AC Immune S.A. ACIU|VYGR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio NMRA|SCLX (Scilex Holding Company) - Enterprise Value to EBITDA Ratio|TVGN (Tevogen Bio Holdings) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACOG (Alpha Cognition Corp) - EV/EBITDA Multiple|Cognition Therapeutics, Inc. - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple IKT|SAVA (Cassava) - Business Value to Operating Income Before Depreciation|Assertio Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation COYA|VistaGen Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ovid Therapeutics OVID|ABOS: EV/EBITDA Multiple|CervoMed Corporation (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Limited|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|EV/EBITDA Multiple PEPG|JUNS (Jupiter Neurosciences) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Corp RLMD|EV/EBITDA Multiple Annovis Bio Corporation ANVS|gracetx.com - EV/EBITDA Multiple|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics, Ltd. - Business Value to Operating Income Before Depreciation|RVPH (Reviva Pharmaceuticals Holdings) - EV/EBITDA Multiple|MetaVia Inc (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NRXS|Total Company Value to Operating Income Before Depreciation Ratio Helius Medical Technologies Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization passagebio.com PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Athira - Enterprise Value to Operating Income Before Depreciation Ratio|ADXN: EV/EBITDA Multiple|ALZN (Alzamend Neuro, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|PTIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTTA|Enterprise Value to Operating Income Before Depreciation Ratio CRGT|Avenue Therapeutics Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (Chromocell Therapeutics Corp)|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharmaceuticals Inc|marinuspharma.com (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics, Inc)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)
